KemPharm Inc. (NASDAQ:KMPH) shares traded down 3.9% during trading on Tuesday . The stock traded as low as $3.97 and last traded at $3.98, with a volume of 62,497 shares traded. The stock had previously closed at $4.14.

Several research analysts have commented on the company. Royal Bank Of Canada reaffirmed a “buy” rating on shares of KemPharm in a research report on Sunday, May 8th. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of KemPharm in a report on Saturday, May 14th. Canaccord Genuity reissued a “buy” rating on shares of KemPharm in a report on Saturday, May 14th. Finally, Zacks Investment Research lowered KemPharm from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. KemPharm presently has a consensus rating of “Buy” and a consensus price target of $26.80.

The firm’s 50 day moving average price is $4.14 and its 200-day moving average price is $10.73. The firm’s market cap is $58.57 million.

KemPharm (NASDAQ:KMPH) last issued its quarterly earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.26. Analysts anticipate that KemPharm Inc. will post ($2.79) EPS for the current year.

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.